Meeting
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
Authors
Elias Chandran
National Cancer Institute, Bethesda, MD
Elias Chandran , Nicholas I. Simon , Scot Anthony Niglio , Lisa Ley , Lisa M. Cordes , Rouf Banday , Chimene Kesserwan , Kent William Mouw , Andre Rashad Kydd , Salah Boudjadi , Ludmila Prokunina-Olsson , Mamta Parikh , Thomas W. Flaig , Rana R. McKay , Arash Rezazadeh , S. Percy Ivy , Giovanni Maria Iannantuono , Saad Omar Atiq , Seth M. Steinberg , Andrea B. Apolo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03375307
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4607)
DOI
10.1200/JCO.2023.41.16_suppl.TPS4607
Abstract #
TPS4607
Poster Bd #
96a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2023 ASCO Annual Meeting
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).
First Author: Anup Kasi
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George